Urging The Convening Of A Mental Health Emerging Therapies Task Force To Prepare The State For The Integration Of Breakthrough Therapies And To Explore Opportunities To Expand Clinical Trials, Research Partnerships, And Treatment Capacity In The State.
SR162 is a Senate resolution urging the Thompson School of Social Work and Public Health to convene a Mental Health Emerging Therapies Task Force. The task force would prepare Hawaii for the possible future integration of breakthrough mental health treatments, especially MDMA-assisted therapy for PTSD and psilocybin-assisted therapy for treatment-resistant depression, and would examine how the state can expand clinical trials, research partnerships, and treatment capacity.
The resolution directs the proposed task force to study federal rescheduling and approval developments, identify opportunities for local research and university partnerships, recommend workforce training and certification pathways, and develop a statewide implementation roadmap. It also calls for the task force to consider best practices from other states and to make legislative and administrative recommendations for long-term adoption of emerging therapies, with reports due to the Legislature before the 2027 and 2028 regular sessions.
SR162 does not directly change Hawaii statutes or create a regulatory program; instead, it expresses legislative intent and requests the formation of a task force to study and prepare for future policy changes. Its practical impact would be to coordinate state agencies, the University of Hawaii, health professionals, and community stakeholders around emerging psychedelic-assisted therapies, while potentially laying the groundwork for future legislation, administrative rules, research initiatives, and workforce development.
The overall sentiment reflected in the resolution is supportive and proactive. The bill frames emerging therapies as a promising response to Hawaii’s mental health crisis and emphasizes preparation, research, safety, equity, and culturally informed care. No committee testimony or vote history is provided, so there is no recorded opposition or divided vote in the available materials.
The main points of potential contention are not expressed in the available discussion record, but the resolution itself suggests likely areas of debate: the use of psychedelic or other breakthrough therapies, the timing of state preparation before full federal approval, and how to balance access with patient safety and regulatory oversight. The inclusion of legal and regulatory experts, Native Hawaiian health organizations, veterans, first responders, and caregivers indicates an effort to address concerns about implementation, cultural appropriateness, and equitable access.